河北医科大学学报 ›› 2024, Vol. 45 ›› Issue (10): 1212-1218.doi: 10.3969/j.issn.1007-3205.2024.10.014

• • 上一篇    下一篇

超声细微特征鉴别卵巢多房囊性、囊实性肿瘤来源的价值

  

  1. 河北医科大学第四医院妇产超声科,河北 石家庄 050011

  • 出版日期:2024-10-25 发布日期:2024-10-15
  • 作者简介:王礼贤(1985-),女,河北威县人,河北医科大学第四医院副主任医师,医学博士,从事妇产科超声诊断研究。
  • 基金资助:
    河北省医学科学研究课题计划项目(20240611)

The value of ultrasonic fine features in identifying the source of multilocular and multilocular-solid ovarian masses

  1. Department of Gynecology and Obstetrics Ultrasonography, the Fourth Hospital of Hebei Medical University, Shijiazhuang 050011, China

  • Online:2024-10-25 Published:2024-10-15

摘要: 目的 探讨超声细微特征在鉴别卵巢多房囊性、囊实性肿瘤来源的价值。
方法 选取河北医科大学第四医院超声诊断为卵巢多房囊性、囊实性肿瘤的患者246例作为研究对象,观察并记录肿瘤的超声细微特征。结合其临床特征和组织学分类,分析超声细微特征与卵巢原发性肿瘤、转移瘤的关系。 
结果 246例卵巢肿瘤的组织学类型:原发性肿瘤217例(88.21%)和转移瘤29例(11.79%);在原发性肿瘤中,良性肿瘤62例(25.20%),以浆液性和黏液性囊腺瘤为主;交界性肿瘤27例(10.98%);恶性肿瘤128例(52.03%),以浆液性和黏液性囊腺癌为主;在转移瘤中,以原发部位结-直肠为主。临床特征:与原发性肿瘤相比,转移瘤的发病年龄较高,差异有统计学意义[(60.80±8.04)岁 vs. (51.29±12.32)岁,P=0.035];原发性肿瘤组均无其他部位肿瘤的确诊病史,而转移瘤组中有9例在发现卵巢肿瘤时已有其他部位肿瘤确诊史(P<0.001);转移瘤组的血清CA199≥37 000 U/L者多于原发性肿瘤组,差异有统计学意义[24(11.06%) vs. 17(58.62%),P<0.001];其余临床特征2组间比较差异均无统计学意义(P>0.05)。超声细微特征:与原发性肿瘤相比,卵巢转移瘤具有瘤体较大[(15.7±4.80) cm vs. (9.54±3.96) cm,P<0.001]、瘤内囊腔个数≥10者较多(55.17% vs. 18.89%,P<0.001)、壁结节少见(6.90% vs. 21.66%,P=0.007)但直径较大[(1.44±0.36) cm vs. (0.97±0.39) cm,P=0.031]以及彩色多普勒血流阻力指数低(0.46±0.07 vs. 0.61±0.13,P<0.001)的特点。 
结论 当超声诊断卵巢多房囊性、囊实性肿物时,特别是同时伴发其他部位恶性肿瘤,利用超声细微特征可提高鉴别卵巢肿物来源的能力。


关键词: 卵巢肿瘤, 超声检查, 转移瘤

Abstract: Objective To explore the value of ultrasonic fine features in identifying the source of multilocular and multilocular-solid ovarian masses. 
Methods A total of 246 patients diagnosed with multilocular and multilocular-solid ovarian masses by ultrasound the Fourth Hospital of Hebei Medical University were selected as the research subjects. The ultrasonic fine features of these masses were observed and recorded. Combined with the clinical features and histopathological classifications, the relationship between the ultrasonic fine features and primary or metastatic ovarian neoplasms were compared and analyzed. 
Results The histological types of 246 patients with ovarian masses included primary ovarian neoplasms in 217 (88.21%) and metastatic ovarian neoplasms in 29 (11.79%) patients. Among primary tumors, 62 patients (25.20%) had benign tumors, mainly consisting of serous and mucinous cystadenomas; 27 patients (10.98%) had borderline tumors; 128 patients (52.03%) had malignant tumors, mainly consisting of serous and mucinous cystadenocarcinoma. In metastatic tumors, the primary site was mainly the colon and rectum. For clinical features, patients with ovarian metastases were older than those with primary ovarian neoplasms [(60.80±8.04) years vs. (51.29±12.32) years, P=0.035]. Patients in primary tumor group had no confirmed history of tumors in other areas, while 9 patients in the metastatic tumor group had history of tumors in other areas when ovarian tumors were detected (P<0.001). The proportion of patients with serum CA199≥37 000 U/L in the metastatic tumor group was higher than that in the primary tumor group, and the difference is statistically significant [24(11.06%) vs. 17(58.62%), P<0.001], and there was no significant difference in other clinical features between the two groups (P>0.05). In terms of sutble ultrasonic features, compared with primary neoplasms, patients with ovarian metastatic tumors had the characteristics of larger tumor size [(15.7±4.80) cm vs. (9.54±3.96) cm, P<0.001], more than 10 cystic cavities inside the tumor (55.17% vs. 18.89%, P<0.0001), fewer mural nodules (6.90% vs. 21.66%, P=0.007) but larger diameters [(1.44±0.36) cm vs. (0.97±0.39) cm, P=0.031], and lower resistance index of color doppler flow (0.46±0.07 vs. 0.61±0.13, P<0.001). 
Conclusion In the ultrasound diagnosis of multilocular and multilocular-solid ovarian masses, especially accompanied by malignant tumors in other areas, the ultrasonic fine features can be used to improve the ability to identify the source of the masses. 


Key words: ovarian neoplasms, ultrasonography, metastatic tumor